路透7月28日 - 周二公布的简报文件显示,在美国食品药品监督管理局(FDA)7月30日召开会议之前,该局评审人员对Replimune公司用于治疗某种皮肤癌的 REPL.O 药物的疗效提出了质疑。
该公司股价在盘前交易中下跌19.7%
路透7月28日 - 周二公布的简报文件显示,在美国食品药品监督管理局(FDA)7月30日召开会议之前,该局评审人员对Replimune公司用于治疗某种皮肤癌的 REPL.O 药物的疗效提出了质疑。
该公司股价在盘前交易中下跌19.7%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.